Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Susan Saline who wrote (7839)	4/7/2000 8:10:00 PM
From: ge	Read Replies (1) \| Respond to of 8116

Susan, please look at the historical value of Cytogen and tell me why you would think the 8/share is low. What is it that they didn't have one year ago that they have today? I think that if you are a trader with stops in place and a limited move up from lows( not 8/share) in mind, go for it. But if you are thinking about a big gain in the next three years, ( in light of the Wis. selling) forget it. If you are looking for a target let me suggest 4 to 4.5. I do not suggest that this will be the low for the stock in the next three years but may be a good point for another pop. Sorry but I do not see a thing to be optimistic about. IMHO

To: Susan Saline who wrote (7839)	4/10/2000 10:09:00 AM
From: Bruce Cullen	Respond to of 8116

Susan, You are right, an increase as a secondary could be huge for Cyto, afterwards you can expect many major upgrades. With the biotech sector catching fire, badly needing recognition I expect the entire industry to emerge as a leader in our markets. Cytogen in it's category will have added growth exposure due to it's many application development possibilities. Targeted therapeutics and medicational remedies are big business in our current biotech state of timeliness. I would expect a price target of my opinion on CYTO to be reaching near 18 short--mid term. Bruce Cullen sherwoodcoastsgroup.com Research & Technical Analyst (Comments are always an opinion, Do your homework!)

To: Susan Saline who wrote (7839)	4/10/2000 11:03:00 AM
From: Bill Ounce	Read Replies (2) \| Respond to of 8116

Long term, a secondary during a hot market could be a good thing for the company. If the money raised is well invested, the company can do really well. But, it it's just used for executive options packages, it will hurt shareholders long term. Short term, it should hurt shareholders. If the market values the pie at $8/slice adding slices should reduce the price/slice. CYTO does appear to be moving with the sector currently, but I've seen some Internet companies break with their sector after secondary offerings. I really like CYTO, but some of the cautions raised itulip.com apply. (Not that you should take that parody too seriously, but some stuff it says may be accurate.)